Compare Amgen, Inc. (AMGN) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs KLA Corp. — how do they compare? Amgen, Inc. trades at $359.15 (market cap $196.12B), while KLA Corp. trades at $221.45 (market cap $302.43B). The key difference: KLA Corp. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | KLAC | |
|---|---|---|
Market Cap | $196.12B | $302.43B |
Sector | Health | Technology |
52-Week High | $388.16 | $301.71 |
52-Week Low | $271.18 | $84.39 |
Enterprise Value | $241.41B | $303.62B |
Dividend Yield | 2.77% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KLA Corporation (KLAC) trades at $231.52, up 0.88% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.94 exceeding the $0.917 estimate. Revenue grew to $12.16 billion in 2025, driving a net income margin of 35.66%. A 1:10 stock split is scheduled for June 12, 2026, and a $2.30 dividend was paid in June 2026.
KLAC's outlook is supported by AI-driven semiconductor equipment demand and consistent earnings outperformance, but high valuation ratios (P/E 65.57, P/S 23.38) pose risks if growth slows. Analysts maintain a buy consensus with a $239.86 price target, though competitive pressures and market volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
